Received Oct 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Shingrix administered to patient when patient had ongoing episode of Shingles; 2nd dose after 1 year; I have Shingles after vaccination; This non-serious case was reported by a consumer and described the occurrence of shingles in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concomitant products included diltiazem (Cardizem). On 01-NOV-2023, the patient received the 1st dose of Shingrix. On 03-OCT-2025, the patient received the 2nd dose of Shingrix. On 20-SEP-2025, 689 days after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: I have Shingles after vaccination). On 03-OCT-2025, the patient experienced drug use for unapproved indication (Verbatim: Shingrix administered to patient when patient had ongoing episode of Shingles) and drug dose administration interval too long (Verbatim: 2nd dose after 1 year). The outcome of the shingles was not resolved and the outcome of the drug use for unapproved indication and drug dose administration interval too long were not applicable. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK receipt date: 03-OCT-2025 Patient had forgotten how painful Shingles were. The second time the pain wasn't as bad as the first time. Don't misunderstand this time has gotten to a 8 or 9 out of 10. Also, patient was on a lot of medicines.
CARDIZEM
Test Name: pain scale; Result Unstructured Data: (Test Result:8 or 9 out of 10,Unit:unknown,Normal Low:0,Normal High:10)